Amgen
In a new study, Dana-Farber researchers and collaborators explain the myriad molecular reasons why KRAS-mutated cancers develop resistance to targeted therapy.
ASCO Study Details Activity of Amgen's Lumakras, First Approved KRAS-Targeted Drug, in NSCLC
Researchers found that advanced NSCLC patients with a KRAS G12C mutation taking Lumakras were alive for a median of 12.5 months.
FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen
The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.
In Brief This Week: AstraZeneca, Amgen, Oncocyte, Rain Therapeutics
News items for the week of April 19, 2021
Ligand Expression Predicts Vectibix Benefit in Colon Cancer, Roche and U of Leeds Study Says
An artificial intelligence- and IHC-based assay predicted improved benefit with Amgen's panitumumab among patients with high AREG and EREG ligand expression.